Background: Eccrine hidrocystomas are rarely described benign cystic lesions, mainly presenting in middle-aged women in the centrofacial area and usually associated with a chronic course, seasonal variability and no proved and consistently efficacious treatments. Case Report: We report 2 patients, a 45- and a 56-year-old woman, with multiple facial eccrine hidrocystomas suggested by dermatoscopy, confirmed by histology and treated with botulinum toxin A with excellent results. Conclusion: Our report stresses the role of dermatoscopy in the diagnosis and follow-up of these lesions, as well as the impact of repeated treatments with botulinum toxin A in eccrine hidrocystomas suggesting it as a first-line treatment for multiple eccrine hidrocystomas because it is easy to use and has no risk of scars.

Keywords:
Hidrocystomas, Dermatoscopy, Botulinum toxin
1.
Lee MR, Ryman W: Multiple eccrine hidrocystomas. Australas J Dermatol 2004;45:178–180.
2.
de Eusébio E, López-Bran E, Rojo S, Suárez R, Sánchez Yus E, Robledo A: Multiple hidrocystomas. Dermatology 1996;193:152–153.
3.
Fariña MC, Piqué E, Olivares M, et al: Multiple hidrocystoma of the face: three cases. Clin Exp Dermatol 1995;20:323–327.
4.
Alfadley A, Al Aboud K, Tulba A, Mourad MM: Multiple eccrine hidrocystomas of the face. Int J Dermatol 2001;40:125–129.
5.
Choi JE, Ko NY, Son SW: Lack of effect of the pulsed-dye laser in the treatment of multiple eccrine hidrocystomas: a report of two cases. Dermatol Surg 2007;33:1513–1515.
6.
Murayama N, Tsuboi R, Unno K, Ogawa H: Multiple eccrine hidrocystomas. Br J Dermatol 1994;131:585–586.
7.
Smith JD, Chernosky ME: Hidrocystomas. Arch Dermatol 1973;108:676–679.
8.
Echague AV, Astner S, Chen AA, Anderson RR: Multiple apocrine hidrocystoma of the face treated with a 1,450-nm diode laser. Arch Dermatol 2005;141:1365–1367.
9.
Tanzi E, Alster TS: Pulsed dye laser treatment of multiple eccrine hidrocystomas: a novel approach. Dermatol Surg 2001;27:898–900.
10.
Lee HW, Lee DK, Lee HJ, et al: Multiple eccrine hidrocystomas: successful treatment with the 595-nm long-pulsed dye laser. Dermatol Surg 2006;32:296–297.
11.
Baum U, Königsdörffer E, Bocker T, Strobel J, Wollina U: Argon laser therapy of multiple eccrine cysts of sweat gland efferent ducts (eccrine hidrocystomas). Klin Monatsbl Augenheilkd 1996;209:249–251.
12.
Blugerman G, Schavelzon D, D’Angelo S: Multiple eccrine hydrocystomas: a new therapeutic option with botulinum toxin. Dermatol Surg 2003;29:557–559.
13.
Khunger N, Mishra S, Jain RK, Saxena S: Multiple eccrine hidocystomas: report of two cases treated unsuccessfully with atropine ointment. Indian J Dermatol Venereol Leprol 2004;70:367–369.
14.
Sperling LC, Sakas EL: Eccrine hidrocystomas. J Am Acad Dermatol 1982;7:763–770.
15.
Clever HW, Shal WJ: Multiple eccrine hidrocystomas: a nonsurgical treatment. Arch Dermatol 1991;127:422–424.
16.
Masri-Fridling GD, Elgart ML: Eccrine hidrocystomas. J Am Acad Dermatol 1992;26:780–782.
17.
Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K: Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998;134:301–304.
18.
Wollina U, Konrad H: Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol 2005;6:141–150.
19.
Pena MA, Alam M, Yoo SS: Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis. Semin Cutan Med Surg 2007;26:29–33.
20.
Malvehy J, Puig S, Argenziano G, Marghood AA, Soyer HP: Dermoscopy report: proposal for standardization. J Am Acad Dermatol 2007;57:84–95.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.